Mostrar el registro sencillo del ítem
dc.contributor.author | Martín-Escolano, Rubén | |
dc.contributor.author | Vidal-Alcántara, Erick Joan | |
dc.contributor.author | Crespo, Javier | |
dc.contributor.author | Ryan, Pablo | |
dc.contributor.author | Real, Luis Miguel | |
dc.contributor.author | Lazo-Álvarez, Juan Ignacio | |
dc.contributor.author | Cabezas-González, Joaquín | |
dc.contributor.author | Macías, Juan | |
dc.contributor.author | Arias-Loste, María Teresa | |
dc.contributor.author | Cuevas, Guillermo | |
dc.contributor.author | Virseda-Berdices, Ana | |
dc.contributor.author | Briz, Veronica | |
dc.contributor.author | Resino, Salvador | |
dc.contributor.author | Jimenez-Sousa, Maria Angeles | |
dc.contributor.author | Fernandez-Rodriguez, Amanda | |
dc.date.accessioned | 2023-11-27T10:00:32Z | |
dc.date.available | 2023-11-27T10:00:32Z | |
dc.date.issued | 2023-11-17 | |
dc.identifier.citation | Immun Ageing. 2023 Nov 17;20(1):62. | es_ES |
dc.identifier.issn | 1742-4933 | es_ES |
dc.identifier.uri | http://hdl.handle.net/20.500.12105/16732 | |
dc.description.abstract | Background: About 25% of patients with acute hepatitis C virus (HCV) infection show spontaneous clearance within the first six months of infection but may remain at risk of inflammaging, aging, and liver and non-liver disease complications. This study evaluated the differences in the plasma levels of immune checkpoints (ICs) and senescence-associated secretory phenotype (SASP) biomarkers between patients who had spontaneously eliminated HCV infection (SC group) and individuals without evidence of HCV infection (C group). Methods: We performed a multicenter retrospective study of 56 individuals: 32 in the SC and 24 in the C groups. ICs and SASP proteins were analyzed using a Luminex 200TM analyzer. The statistical analysis used Generalized Linear Models with gamma distribution (log-link) adjusted by significant variables and sex. Results: 13 ICs (BTLA, CD137(4-1BB), CD27, CD28, CD80, GITR, HVEM, IDO, LAG-3, PD-1, PD-L1, PD-L2, and TIM-3) and 13 SASP proteins (EGF, Eotaxin, IL-1alpha, IL-1RA, IL-8, IL-13, IL-18, IP-10, SDF-1alpha, HGF, beta-NGF, PLGF-1, and SCF) were significantly higher in SC group after approximately more than two years of HCV clearance. After stratifying by sex, differences remained significant for males, which showed higher levels for 13 ICs and 4 SASP proteins in SC. While only PD-L2 was significantly higher in SC women, and no differences in SASP were found. Conclusions: Higher plasma levels of different IC and SASP proteins were found in individuals after more than two years of HCV clearance, mainly in men. Alterations in these molecules might be associated with an increased risk of developing liver and non-hepatic diseases. | es_ES |
dc.description.sponsorship | This study was supported by grants from Instituto de Salud Carlos III (ISCIII; grant number CP14/0010) to AFR), Fundación Universidad Alfonso X el Sabio (FUAX) – Santander (grant number 1.010.932 to AFR) and by PID2021–126781OB-I00 funded by MCIN/AEI/10.13039/501100011033 and by “ERDF A way of making Europe”. The study was also funded by the CIBER -Consorcio Centro de Investigación Biomédica en Red- (CB 2021), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación and Unión Europea–Next‑GenerationEU (CB21/13/00044, CB21/13/00118, and GVC16/EHD/4). M.A.J.-S. is Miguel Servet researcher supported and funded by ISCIII (grant numbers CP17CIII/00007). RME is Juan de la Cierva researcher supported and fnanced by MICINN of Spain (FJC2020-042865-I). | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | BioMed Central (BMC) | es_ES |
dc.type.hasVersion | VoR | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.subject | Biomarkers | es_ES |
dc.subject | HCV | es_ES |
dc.subject | Immune checkpoint proteins | es_ES |
dc.subject | SASP proteins | es_ES |
dc.subject | Spontaneous clearance | es_ES |
dc.title | Immunological and senescence biomarker profiles in patients after spontaneous clearance of hepatitis C virus: gender implications for long-term health risk | es_ES |
dc.type | research article | es_ES |
dc.rights.license | Atribución 4.0 Internacional | * |
dc.identifier.pubmedID | 37978401 | es_ES |
dc.format.volume | 20 | es_ES |
dc.format.number | 1 | es_ES |
dc.format.page | 62 | es_ES |
dc.identifier.doi | 10.1186/s12979-023-00387-z | es_ES |
dc.contributor.funder | Instituto de Salud Carlos III | es_ES |
dc.contributor.funder | Fundación Universidad Alfonso X el Sabio | es_ES |
dc.contributor.funder | Fundación Banco Santander | es_ES |
dc.contributor.funder | Unión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF) | es_ES |
dc.contributor.funder | Ministerio de Ciencia e Innovación (España) | es_ES |
dc.contributor.funder | Centro de Investigación Biomédica en Red - CIBERINFEC (Enfermedades Infecciosas) | es_ES |
dc.contributor.funder | Unión Europea. Comisión Europea. NextGenerationEU | es_ES |
dc.contributor.funder | Agencia Estatal de Investigación (España) | es_ES |
dc.description.peerreviewed | Sí | es_ES |
dc.relation.publisherversion | https://doi.org/10.1186/s12979-023-00387-z | es_ES |
dc.identifier.journal | Immunity & ageing : I & A | es_ES |
dc.repisalud.centro | ISCIII::Centro Nacional de Microbiología | es_ES |
dc.repisalud.institucion | ISCIII | es_ES |
dc.rights.accessRights | open access | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/PID2021–126781OB-I00 | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/FJC2020-042865-I | es_ES |
dc.relation.projectFIS | info:eu-repo/grantAgreement/ES/CP14/0010 | es_ES |
dc.relation.projectFIS | info:eu-repo/grantAgreement/ES/CP17CIII/00007 | es_ES |
dc.relation.projectFIS | info:eu-repo/grantAgreement/ES/CB21/13/00044 | es_ES |
dc.relation.projectFIS | info:eu-repo/grantAgreement/ES/CB21/13/00118 | es_ES |
dc.relation.projectFIS | info:eu-repo/grantAgreement/ES/GVC16/EHD/4 | es_ES |